Skip to main content
. 2021 Apr 19;13(8):1962. doi: 10.3390/cancers13081962

Table 3.

Current clinical trials combining or comparing systemic treatments with TACE.

Trial Identifier Phase BCLC Stage Treatment Arms Primary Endpoint(s) Setting
LEAP-012 NCT04246177 Phase 3 B

  • Lenvatinib + pembrolizumab + TACE

  • TACE

  • PFS per RECIST 1.1

  • OS

 First-line
EMERALD-1 NCT03778957 Phase 3 B

  • Durvalumab + TACE

  • Durvalumab + bevacizumab + TACE

  • TACE

  • PFS per RECIST 1.1

 First-line
CheckMate 74W NCT04340193 Phase 3 B

  • Nivolumab + ipilimumab + TACE

  • Nivolumab + TACE

  • TACE

  • Time to TACE progression

  • OS

 First-line
ABC-HCC NCT04803994 Phase 3 B

  • Atezolizumab + bevacizumab

  • TACE

  • Time to failure of treatment strategy

 First-line
RENOTACE NCT04777851 Phase 3 B

  • Regorafenib + nivolumab

  • TACE

  • PFS per mRECIST

 First-line

BCLC, Barcelona Clinic Liver Cancer; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours; TACE, transarterial chemoembolization.